IL-2 variant with T-cell selectivity displays antitumor activity and good tolerance in animals Dec. 12, 2000
Final analysis of phase I results for BrevaRex presented to American Society of Hematology Dec. 7, 2000
Antigenics expands pancreatic cancer phase I/II trial following positive data with Oncophage vaccine Dec. 6, 2000
RSS